Adenosine receptors as therapeutic targets
Open accessThe DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, A1 and A2A receptors are considered the principal targets mediating caffeine’s physiological effects.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“A key mechanism underlying the interaction between caffeine and exercise is caffeine’s pharmacological action as a competitive adenosine receptor antagonist.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Instead, competitive blockade of A1 and A2A adenosine receptors is widely regarded as the central mechanism underlying caffeine’s physiological effects during both habitual intake and exercise (Figure 1) [28,29,30,31].”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Within the range of plasma concentrations relevant to sports nutrition practice, typically micromolar levels achieved after low-to-moderate caffeine intake, caffeine’s primary mechanism of action is unlikely to involve phosphodiesterase (PDE) inhibition or direct intracellular Ca2+ release.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“This effect modulates key physiological processes such as anti-inflammatory responses, angiogenesis, and vasodilation, as illustrated in Figure 2 (left panel) [52,66,67,68].”
From Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives (2025) · cites this paper as [68]
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Self-citationCalker, D. V., Müller, M., & Hamprecht, B. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb05236.x · Cited by 1,371
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Astrocytic Purinergic Signaling Coordinates Synaptic Networks
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J.-Y., Takano, H., Moss, S. J., McCarthy, K., & Haydon, P. G. (2005) · Science · doi:10.1126/science.1116916 · Cited by 1,280
Adenosine: A Mediator of the Sleep-Inducing Effects of Prolonged Wakefulness
Porkka-Heiskanen, T., Strecker, R. E., Thakkar, M., Bjørkum, A. A., Greene, R. W., & McCarley, R. W. (1997) · Science · doi:10.1126/science.276.5316.1265 · Cited by 1,252
Subclasses of external adenosine receptors.
Londos, C., Cooper, D. M., & Wolff, J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.5.2551 · Cited by 1,081
Extracellular metabolism of ATP and other nucleotides
Zimmermann, H. (2000) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100000309 · Cited by 990
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
Ledent, C., Vaugeois, J.-M., Schiffmann, S. N., Pedrazzini, T., Yacoubi, M. E., Vanderhaeghen, J.-J., Costentin, J., Heath, J. K., Vassart, G., & Parmentier, M. (1997) · Nature · doi:10.1038/41771 · Cited by 918
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 899
Research works printed but not linked: 1
- Ji, X. D. & Jacobson, K. A. [3H]-ZM241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des. Discov. 16, 217–226 (1999).
Cited by
Items 101–200 of 1,001
Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells
Sitkovsky, M. V., Lukashev, D. E., Deaglio, S., Dwyer, K. M., Robson, S. C., & Ohta, A. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.23 · Cited by 136
“of A2 adenosine receptor agonists and drugs that increase levels of intracellular adenosine (Cronstein and Weissmann, 1995; Sullivan and Linden, 1998; Cronstein et al., 1999; Fredholm et al., 2001; Linden, 2001; Jacobson and Gao, 2006).”
BackgroundIntroduction to Adenosine Receptors as Therapeutic Targets
Jacobson, K. A. (2009) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-89615-9_1 · Cited by 123
“The structure–activity relationships (SARs) of adenosine derivatives as agonists of the ARs have been thoroughly probed (Jacobson and Gao 2006; Yan et al. 2003), and representative agonists are shown in Fig.”
BackgroundInfluentialSelf-citationGranata, F., Frattini, A., Loffredo, S., Staiano, R. I., Petraroli, A., Ribatti, D., Oslund, R., Gelb, M. H., Lambeau, G., Marone, G., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902501 · Cited by 124
“To further investigate the adenosine receptor(s) involved in the angiogenic switch ofHLMs stimulatedwith sPLA2s,we evaluated the effect of agonists of A2A (CGS21680) andA3 receptors (Cl-IB-MECA) (54).”
MethodThermostabilisation of an Agonist-Bound Conformation of the Human Adenosine A2A Receptor
Lebon, G., Bennett, K. A., Jazayeri, A., & Tate, C. G. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.03.075 · Cited by 125
Guanosine: a Neuromodulator with Therapeutic Potential in Brain Disorders
Lanznaster, D., Dal-Cim, T. A., Piermartiri, T., & Tasca, C. I. (2016) · Aging and Disease · doi:10.14336/ad.2016.0208 · Cited by 136
“From then on, adenosine and ATP have been recognized as intercellular messenger molecules and a pivotal role of these purinergic messengers in the CNS has been highlighted elsewhere [6-10].”
BackgroundRapamycin-inspired macrocycles with new target specificity
Guo, Z., Hong, S. Y., Wang, J., Rehan, S., Liu, W., Peng, H., Das, M., Li, W., Bhat, S., Peiffer, B., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-018-0187-4 · Cited by 120
Water Network Perturbation in Ligand Binding: Adenosine A2AAntagonists as a Case Study
Bortolato, A., Tehan, B. G., Bodnarchuk, M. S., Essex, J. W., & Mason, J. S. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci4001458 · Cited by 119
Internalization and desensitization of adenosine receptors
Klaasse, E., IJzerman, A. P., DeGrip, W. J., & Beukers, M. W. (2007) · Purinergic Signalling · doi:10.1007/s11302-007-9086-7 · Cited by 150
“[5], Jacobson and Gao [7], Beukers et al.”
BackgroundLópez-Cruz, L., Salamone, J. D., & Correa, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00526 · Cited by 115
Valant, C., May, L. T., Aurelio, L., Chuo, C. H., White, P. J., Baltos, J., Sexton, P. M., Scammells, P. J., & Christopoulos, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320962111 · Cited by 125
“Because the adenosine A3 receptor (A3AR) shares closest sequence homology to and signal transduction mechanisms with the A1AR and has also been implicated in cardiac physiology (36), we also assessed activity at the A3AR.”
BackgroundAdvanced development in chemical analysis of Cordyceps
Zhao, J., Xie, J., Wang, L. Y., & Li, S. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.04.025 · Cited by 116
Lyman, E. R., Higgs, C., Kim, B., Lupyan, D., Shelley, J. C., Farid, R., & Voth, G. A. (2009) · Structure · doi:10.1016/j.str.2009.10.010 · Cited by 114
“Considering that a wide variety of ligands, from metal ions (Schwartz et al., 2006) to small molecules ( Jacobson and Gao, 2006 ) to peptides (Schwartz, 1994), are able to inactivate GPCRs by binding to various sites within the binding pocket and on the extracellular loops (Schwartz, 1994), it seems reasonable that an…”
BackgroundInfluentialHuntington’s disease: pathogenesis to animal models
Kumar, P., Kalonia, H., & Kumar, A. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70238-3 · Cited by 129
Malekpour, K., Hazrati, A., Zahar, M., Markov, A. A., Zekiy, A. O., Navashenaq, J. G., Roshangar, L., & Ahmadi, M. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10185-z · Cited by 127
“Also, MSCs exosomes catalysis the adenosine production (activating survival kinases from Mediated by adenosine receptors) [112] from extracellular ATP released from damaged tissues (stimulates immune cells to kill damaged and stimulated cells) [113] with CD73 on their surface [114, 115].”
BackgroundAntiepileptic effects of silk-polymer based adenosine release in kindled rats
Szybala, C., Pritchard, E. M., Lusardi, T. A., Li, T., Wilz, A., Kaplan, D. L., & Boison, D. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.018 · Cited by 113
“A1 receptor activation is not only effective in seizure suppression (Jacobson and Gao, 2006), but also is essential in keeping an epileptogenic focus localized (Fedele et al., 2006).”
BackgroundEmerging adenosine receptor agonists
Gao, Z., & Jacobson, K. A. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.3.479 · Cited by 121
“The wide and abundant distri bution of these receptors suggests that they potentially play a critical role in the body and, thus, potentially useful therapeutic agents may be developed based on the AR distribution and AR function [12] .”
BackgroundInfluentialSelf-citationA2A Adenosine Receptor Regulates the Human Blood-Brain Barrier Permeability
Kim, D.-G., & Bynoe, M. S. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8879-2 · Cited by 111
“Extracellular adenosine acts locally due to its short half-life (approximately 10 s) [9, 10].”
Are purines mediators of the anticonvulsant/neuroprotective effects of ketogenic diets?
Masino, S. A., & Geiger, J. D. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.009 · Cited by 116
A 2A adenosine receptor functional states characterized by 19 F-NMR
Sušac, L., Eddy, M. T., Didenko, T., Stevens, R. C., & Kurt Wüthrich, A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813649115 · Cited by 111
“A2AAR functions have been studied in the central nervous system as a key modulator of neurotransmitters (2), in the cardiovascular system as regulating vasodilation (3), and in the immune system as a T-cell surface immune checkpoint protein (4).”
BackgroundAdenosine receptor agonists for promotion of dermal wound healing
Valls, M. D., Cronstein, B. N., & Montesinos, M. C. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.002 · Cited by 109
“of epithelial cells in skin and visceral organs, inflammation, neuroprotection and cancer [13, 14].”
BackgroundGessi, S., Merighi, S., Varani, K., Cattabriga, E., Benini, A., Mirandola, P., Leung, E., Lennan, S. M., Feo, C. V., Baraldi, S., et al. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20994 · Cited by 128
“However we think that after the introduction of more selective ligands as new tools to identify adenosine receptors (Baraldi and Borea, 2000; Jacobson and Gao, 2006), several actions of adenosine should be reconsidered.”
BackgroundHuman Adenosine A2A Receptor: Molecular Mechanism of Ligand Binding and Activation
Carpenter, B., & Lebon, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00898 · Cited by 127
“A1R and A3R predominantly activate heterotrimeric G proteins belonging to the Gαi/o family, which inhibit cAMP production by adenylate cyclase, in contrast A2AR and A2BR predominantly activate Gαs family members, which stimulate cAMP production (Jacobson and Gao, 2006).”
BackgroundInfluentialYang, M., Ma, C., Liu, S., Shao, Q., Gao, W., Song, B., Sun, J., Xie, Q., Zhang, Y., Feng, A., et al. (2010) · Immunology & Cell Biology · doi:10.1038/icb.2009.77 · Cited by 110
Zhou, Y., Schneider, D. J., Morschl, É., Ling, S., Pedroza, M., Karmouty‐Quintana, H., Le, T. B., Sun, C.-X., & Blackburn, M. R. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002907 · Cited by 117
“There are four adenosine receptors (A1R, A2AR, A2BR, A3R) that are widely distributed on inflammatory and stromal cells (13, 14).”
Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis
Bharate, S. S., Mignani, S., & Vishwakarma, R. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01922 · Cited by 102
(2024) · doi:10.1038/s42256-024-00847-1 · Cited by 108
“This observation aligns with the fact that many adenine derivatives are antagonists for these subtypes, such as WRC-0571 for A 1 R 48 and MRS3777 for A 3 R 49 , and other functional groups have a critical role in distinguishing agonists from antagonists.”
Membrane heterogeneity – from lipid domains to curvature effects
Semrau, S., & Schmidt, T. (2009) · Soft Matter · doi:10.1039/b901587f · Cited by 112
Altavilla, D., Bitto, A., Polito, F., Marini, H., Minutoli, L., Stefano, V., Irrera, N., Cattarini, G., & Squadrito, F. (2009) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152509789541909 · Cited by 107
“More recently, slow adenosine signalling has been implicated in embryological development, wound healing, restenosis, atherosclerosis, ischemia, cell turnover of epithelial cells in skin and visceral organs, inflammation, neuro-protection and cancer [19, 20].”
BackgroundGuerreiro, S., Toulorge, D., Hirsch, É. C., Marien, M. R., Sokoloff, P., & Michel, P. P. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.048207 · Cited by 113
“The protective effects of caffeine were attributed, in part, to the antagonism of A2A adenosine receptors (Jacobson and Gao, 2006), but other mechanisms were not excluded (Xu et al.”
BackgroundInfluentialBitto, A., Polito, F., Irrera, N., D'Ascola, A., Avenoso, A., Nastasi, G., Campo, G. M., Micali, A., Bagnato, G., Minutoli, L., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30538 · Cited by 105
Adenosine Receptors in Health and Disease
Gessi, S., Merighi, S., Varani, K., & Borea, P. A. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385526-8.00002-3 · Cited by 127
de Graaf, C., Foata, N., Engkvist, O., & Rognan, D. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21724 · Cited by 114
Adenosine A2A Receptor Ligation Inhibits Osteoclast Formation
Mediero, A., Kara, F. M., Wilder, T., & Cronstein, B. N. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.10.017 · Cited by 103
“phospholipase C and calcium mobilization (A2B and A3), phosphatidylinositol 3-kinase (A3), and protein kinase C and mitogen-activated protein kinases (A1, A2A, and A3 receptors).(21) Future experiments will be directed at the dissection of adenosine receptor signaling in OCPs and the role of cAMP or other intermediate…”
BackgroundTheofilas, P., Brar, S. K., Stewart, K.-A., Shen, H., Sandau, U. S., Poulsen, D. J., & Boison, D. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02947.x · Cited by 106
“In principle, adenosine A1 receptor (A1R) agonists are very effective in the inhibition of neuronal activity and in the suppression of seizures (Fredholm, 2003; Jacobson & Gao, 2006).”
BackgroundJeong, L. S., Choe, S. A., Gunaga, P., Kim, H. O., Lee, H. W., Lee, S. K., Tosh, D. K., Patel, A. R., Palaniappan, K. K., Gao, Z., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070259t · Cited by 103
Self-citationHistory and Perspectives of A2AAdenosine Receptor Antagonists as Potential Therapeutic Agents
Preti, D., Baraldi, P. G., Moorman, A. R., Borea, P. A., & Varani, K. (2015) · Medicinal Research Reviews · doi:10.1002/med.21344 · Cited by 112
Higgs, C., Beuming, T., & Sherman, W. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100008s · Cited by 101
Ecto-5′-Nucleotidase (CD73) Decreases Mortality and Organ Injury in Sepsis
Haskó, G., Csóka, B., Koscsó, B., Chandra, R., Pacher, P., Thompson, L. F., Deitch, E. A., Spolarics, Z., Virág, L., Gergely, P., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003379 · Cited by 112
A2B Adenosine Receptor and Cancer
Gao, Z., & Jacobson, K. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205139 · Cited by 108
“Although extracellular adenosine exerts its action via four G protein-coupled receptors (GPCRs), A1, A2A, A2B and A3 [12], in this review we will only focus on the importance of A2BAR signaling (Figure 1) in cancer progression and the rationale to use A2BAR antagonists as anticancer agents.”
BackgroundResultSelf-citationA1 Adenosine Receptor Antagonists, Agonists, and Allosteric Enhancers
Kiesman, W. F., Elzein, E. O., & Zablocki, J. A. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_2 · Cited by 111
“The P1 family of adenosine receptors consists of the members A1, A2A, A2B, and A3, which have high sequence homology with many conserved residues at the active sites; however, sufficient differences are found for each active site such that selective agonists and antagonists have been generated for each receptor subtyp…”
Dal-Cim, T. A., Ludka, F. K., Martins, W. C., Reginato, C., Parada, E., Egea, J., López, M. G., & Tasca, C. I. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12324 · Cited by 111
Purinergic receptors in the endocrine and exocrine pancreas
Novak, I. (2007) · Purinergic Signalling · doi:10.1007/s11302-007-9087-6 · Cited by 114
“inhibition of A2B receptors in hepatocytes would control glucose production [74].”
BackgroundNovel ocular antihypertensive compounds in clinical trials
Chen, J., Runyan, & Robinson (2011) · Clinical ophthalmology · doi:10.2147/opth.s15971 · Cited by 106
“7-51 nM) receptors relative to A 2A (2,500–2,900 nM) and A 2B (54,000 nM) receptors.(56,69) Can-Fite is conducting a Phase II safety and efficacy clinical trial of orally administered CF-101 in patients with elevated IOP or POAG (Trial ID: NCT01033422).”
Saucier-Sawyer, J. K., Deng, Y., Seo, Y.-E., Cheng, C. J., Zhang, J., Quijano, E., & Saltzman, W. M. (2015) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1065833 · Cited by 98
“In addition, Ad has been found to bind G-protein coupled receptors A1, A2A, A2B and A3 on different cells in the body [65].”
BackgroundCuzzolin, A., Sturlese, M., Deganutti, G., Salmaso, V., Sabbadin, D., Ciancetta, A., & Moro, S. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00702 · Cited by 105
Pak, J., Lee, J. H., Pak, N. J., Pak, Y., Park, K. S., Jeon, J. H., Jeong, B. C., & Lee, S. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072146 · Cited by 104
“This extracellular ATP is hydrolyzed to adenosine monophosphate (AMP), which is converted to adenosine, a potent activator of signals mediated by AKT and ERK pathways [77,78].”
BackgroundExtracellular adenosine signaling in molecular medicine
Eltzschig, H. K. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-0999-z · Cited by 111
“adenosine receptors [39, 40], or studies utilizing compounds that would indirectly enhance extracellular adenosine con-”
Backgroundde Andrade, K. Q., Almeida-da-Silva, C. L. C., & Coutinho‐Silva, R. (2019) · Mediators of Inflammation · doi:10.1155/2019/7241312 · Cited by 136
“P1 receptors recognize extracellular adenosine; they are subdivided into A1, A2a, A2b, and A3, exhibiting varying degrees of sensitivity to adenosine [155].”
BackgroundMechanistic Insights into Specific G Protein Interactions with Adenosine Receptors
Wang, J., & Miao, Y. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.9b04867 · Cited by 98
Amici, M. D., Dallanoce, C., Holzgrabe, U., Tränkle, C., & Mohr, K. (2009) · Medicinal Research Reviews · doi:10.1002/med.20166 · Cited by 106
“However, they have been discontinued since the widespread distribution of ARs gives rise to a number of side effects and, with agonists, to receptor desensitization upon chronic administration.(129) The study of allosteric modulators of ARs dates back to about 20 years ago when a group of 2-amino-3-benzoylthiophenes,…”
BackgroundAdenosine augmentation therapies (AATs) for epilepsy: Prospect of cell and gene therapies
Boison, D. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.03.019 · Cited by 99
Benarroch, E. E. (2008) · Neurology · doi:10.1212/01.wnl.0000297939.18236.ec · Cited by 96
Role of Pannexin-1 hemichannels and purinergic receptors in the pathogenesis of human diseases
Velasquez, S., & Eugenín, E. A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00096 · Cited by 117
“available pharmaceutical adenosine, such as adenocard and adenoscan, are currently used to treat supraventricular tachycardia, is an example of an ion channel targeted treatment (Delacrétaz, 2006; Jacobson and Gao, 2006).”
BackgroundExtracellular Nucleotides and P2 Receptors in Renal Function
Vallon, V., Unwin, R. J., Inscho, E. W., Leipziger, J., & Kishore, B. K. (2019) · Physiological Reviews · doi:10.1152/physrev.00038.2018 · Cited by 95
Mediero, A., Perez‐Aso, M., & Cronstein, B. N. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12227 · Cited by 93
“Both A2A and A2B receptors stimulate the formation of cAMP and, depending on the cell type, increase intracellular calcium levels and phospholipase C mobilization (Fredholm et al., 2001; Jacobson and Gao, 2006).”
BackgroundHigh spin cobalt(II) as a probe for the investigation of metalloproteins.
Bertini, I., & Luchinat, C. (1984) · PubMed · Cited by 93
Adenosine A2B Receptor: From Cell Biology to Human Diseases
Sun, Y., & Huang, P. (2016) · Frontiers in Chemistry · doi:10.3389/fchem.2016.00037 · Cited by 112
“Among human ARs, A1AR, and A3AR share 49% sequence similarity and A2AAR and A2BAR share 59% similarity (Jacobson and Gao, 2006; Goblyos and Ijzerman, 2009).”
BackgroundJeremic, D., Sanchez-Rodriguez, I., Jimenez-Diaz, L., & Navarro-Lopez, J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107808 · Cited by 89
Methylxanthines, Seizures, and Excitotoxicity
Boison, D. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-13443-2_9 · Cited by 89
“Conversely, A1R agonists are highly effective in the suppression of seizures (Benarroch 2008; Fredholm 2003; Jacobson and Gao 2006), and have been demonstrated to suppress seizures that are resistant to conventional antiepileptic”
BackgroundIvanov, A. A., Barak, D., & Jacobson, K. A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801533x · Cited by 88
Self-citationA1adenosine receptor agonists and their potential therapeutic applications
Elzein, E. O., & Zablocki, J. A. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802497284 · Cited by 101
“Drugs (2008) 17(12) agonists have been generated for each receptor subtype [1-3] .”
BackgroundFractalkine/CX3CR1 is involved in the cross-talk between neuron and glia in neurological diseases
Luo, P., Chu, S.-F., Zhang, Z., Xia, C.-Y., & Chen, N.-H. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.11.017 · Cited by 89
Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
Silvestro, S., Schepici, G., Bramanti, P., & Mazzon, E. (2020) · Molecules · doi:10.3390/molecules25215186 · Cited by 100
“ARs are located in immune cells, blood vessels, astrocytes, microglia, corpus striatum and spinal cord [79].”
BackgroundThe role of the ATP-adenosine axis in ischemic stroke
Schädlich, I. S., Winzer, R., Stabernack, J., Tolosa, E., Magnus, T. U., & Rissiek, B. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-023-00987-3 · Cited by 96
“Beyond the control of glutamatergic excitotoxicity, A2AR antagonists exert their protective effects through inhibition of phospho-p38 MAPK [145] and by reducing JNK MAPK activation in oligodendrocytes [159].”
BackgroundInfluentialHypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells
Ma, D., Kondo, T., Nakazawa, T., Niu, D., Mochizuki, K., Kawasaki, T., Yamane, T., & Katoh, R. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.04.008 · Cited by 102
“There is growing evidence that the adenosine-adenosine receptor pathway may provide promising therapeutic targets in a wide range of conditions such as cerebral and cardiac ischemia, nervous system disorders including dementia and Parkinson disease, and immune and inflammatory disorders [22].”
BackgroundPDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction
Knight, W. E., Chen, S., Zhang, Y., Oikawa, M., Wu, M., Zhou, Q., Miller, C. L., Cai, Y., Mickelsen, D. M., Moravec, C. S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607728113 · Cited by 88
“In contrast, activating cAMP/PKA signaling by stimulating A2R appears to be cardioprotective.”
BackgroundInfluentialA2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier
Kim, D.-G., & Bynoe, M. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci76207 · Cited by 88
“Adenosine is a damage/ danger-signaling molecule that responds to cell stress or tissue damage by inducing a cascade of events involving recruitment of cells and substances across biological barriers needed to repair damaged tissues (46, 48).”
BackgroundCardiac myocyte–secreted cAMP exerts paracrine action via adenosine receptor activation
Sassi, Y., Ahles, A., Truong, D.-J. J., Baqi, Y., Lee, S.-Y., Husse, B., Hulot, J.-S., Foinquinos, A., Thum, T., Müller, C. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74349 · Cited by 86
G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions
Jacobson, K. A., Balasubramanian, R., Deflorian, F., & Gao, Z. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9294-7 · Cited by 110
“Agonists: The SAR of adenosine derivatives as AR agonists has been well explored [1, 54], and selective agonists and antagonists for all four subtypes have been reported (Figs.”
BackgroundMethodInfluentialSelf-citationAdenosine A2AReceptor Activation Prevents Wear Particle–Induced Osteolysis
Mediero, A., Frenkel, S. R., Wilder, T., He, W., Mazumder, A., & Cronstein, B. N. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003393 · Cited by 86
“Antagonists of the receptor are currently in testing for the treatment ofParkinson’s disease (6).”
BackgroundInfluentialHutchinson, D. S., Summers, R. J., & Bengtsson, T. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.05.008 · Cited by 99
Enhanced mast cell activation in mice deficient in the A2b adenosine receptor
Hua, X., Kovářová, M., Chason, K. D., Nguyen, M., Koller, B. H., & Tilley, S. L. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061372 · Cited by 86
“The potency of adenosine as a modulator of mast cell function is well recognized, and adenosine receptors are of considerable interest as therapeutic targets for asthma and allergy (9, 26).”
BackgroundAdenosine A2A Receptor Antagonists for Cancer Immunotherapy
Yu, F., Zhu, C., Xie, Q., & Wang, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00237 · Cited by 92
Structure based prediction of subtype-selectivity for adenosine receptor antagonists
Katritch, V., Kufareva, I., & Abagyan, R. A. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.009 · Cited by 85
“In the past 20 years, intensive drug discovery efforts have resulted in hundreds of SAR profiles and yielded a number of AR ligands with respectable (w100 fold) selectivity for each of the subtypes (Jacobson and Gao, 2006).”
BackgroundInfluentialBeneficial and detrimental role of adenosine signaling in diseases and therapy
Liu, H., & Xia, Y. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00350.2015 · Cited by 88
“including modulation of nervous system, immune response, vascular function and metabolism(64, 93).”
BackgroundG-Protein Coupled Receptors and Tau-different Roles in Alzheimer’s Disease
Chidambaram, H., & Chinnathambi, S. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.04.019 · Cited by 91
Pires, V. A., Pamplona, F. A., Pandolfo, P., Fernandes, D., Prediger, R. D. S., & Takahashi, R. N. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832a80bf · Cited by 84
“…(DPCPX), and selective adenosine A2A receptor antagonists include (7-[2-phenylethyl]-5-amino-2-[2-furyl]-pyrazolo-4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine (SCH 58261) and 4-(2-[7-amino-2-{2-furyl}{1,2,4}triazolo-{2,3-a}{1,3,5}triazin-5-ylamino]ethyl)-phenol (ZM241385) (Jacobson and Gao, 2006).”
BackgroundCiccarelli, R., D’Alimonte, I., Ballerini, P., D’Auro, M., Nargi, E., Buccella, S., Iorio, P. D., Bruno, V., Nicoletti, F., & Caciagli, F. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.031617 · Cited by 92
May, L. T., Bridge, L., Stoddart, L. A., Briddon, S. J., & Hill, S. J. (2011) · The FASEB Journal · doi:10.1096/fj.11-186296 · Cited by 98
“The A3-AR is a potential novel therapeutic target for a number of conditions, including inflammatory disorders and cancer (46, 47).”
BackgroundA Metabolism Toolbox for CAR T Therapy
Xu, X., Gnanaprakasam, J. N. R., Sherman, J., & Wang, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00322 · Cited by 83
“For instance, adenosine is enriched in the TME and suppresses the T cell response partially by engaging cell-surface purinergic receptors-mediated signaling in T cells (220, 221).”
BackgroundAzide−Tetrazole Equilibrium of C-6 Azidopurine Nucleosides and Their Ligation Reactions with Alkynes
Lakshman, M. K., Singh, M. K., Parrish, D. A., Balachandran, R., & Day, B. W. (2010) · The Journal of Organic Chemistry · doi:10.1021/jo902342z · Cited by 82
The emergence of designed multiple ligands for neurodegenerative disorders
Geldenhuys, W. J., Youdim, M. B. H., Carroll, R. T., & der Schyf, C. J. V. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.04.010 · Cited by 96
The anti-schistosomal drug praziquantel is an adenosine antagonist
Angelucci, F., Basso, A. B. G., Bellelli, A., Brunori, M., Pica‐Mattoccia, L., & Valle, C. (2007) · Parasitology · doi:10.1017/s0031182007002600 · Cited by 89
“Selective agonists of adenosine receptors (Jacobson and Gao, 2006) were used in 2 different experiments.”
BackgroundMethodResultAntonioli, L., Colucci, R., Pellegrini, C., Giustarini, G., Tuccori, M., Blandizzi, C., & Fornai, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.002 · Cited by 86
Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy
Arab, S., & Hadjati, J. (2019) · Immune Network · doi:10.4110/in.2019.19.e23 · Cited by 265
Thompson, E. A., & Powell, J. D. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-023155 · Cited by 83
“Adenosine can subsequently bind to purinergic receptors, including A1, A2a, A2b, and A3 (3).”
BackgroundAdenosine, adenosine receptors and glaucoma: An updated overview
Zhong, Y., Yang, Z., Huang, W.-C., & Luo, X. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.01.005 · Cited by 85
Purinergic receptors and gastrointestinal secretomotor function
Christofi, F. L. (2008) · Purinergic Signalling · doi:10.1007/s11302-008-9104-4 · Cited by 80
“Adenosine receptors belong to the superfamily of seven transmembrane domain G protein-coupled receptors (GPCR) and they are emerging as potential therapeutic targets [53].”
BackgroundA Drosophila adenosine receptor activates cAMP and calcium signaling
Doleželová, E., Nothacker, H., Civelli, O., Bryant, P. J., & Žurovec, M. (2007) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2006.12.003 · Cited by 90
“AdoR subtypes are differentially distributed throughout the body (Murphree and Linden, 2004; Jacobson and Gao, 2006).”
BackgroundG Protein–Coupled Receptor Connectivity to NF-κB in Inflammation and Cancer
Fraser, C. C. (2008) · International Reviews of Immunology · doi:10.1080/08830180802262765 · Cited by 85
“The A3 receptor is linked to G-protein α subunit Gi, which inhibits AC, resulting in decreased production of cAMP and decreased activation of PKA [148].”
Gessi, S., Fogli, E., Sacchetto, V., Merighi, S., Varani, K., Preti, D., Leung, E., MacLennan, S., & Borea, P. A. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.194902 · Cited by 79
Enhanced mast cell activation in mice deficient in the A2b adenosine receptor
Hua, X., Kovarova, M., Chason, K. D., Nguyen, M., Koller, B. H., & Tilley, S. L. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061372032807c · Cited by 79
Astrocytic glycogenolysis: mechanisms and functions
Hertz, L., Xu, J., Song, D., Du, T., Li, B., Yan, E., & Peng, L. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9536-1 · Cited by 82
Kim, H. J., Yoon, B. K., Park, H., Seok, J. W., Choi, H., Yu, J. H., Choi, Y. J., Song, S. J., Kim, A., & Kim, J. W. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.2.128 · Cited by 81
“cAMP-dependent protein kinase (PKA), and inhibits phosphatidylinositol-3-kinase (PI3K)/AKT activity (19).”
BackgroundAdenosine inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells
Hashmi, A. Z., Hakim, W., Kruglov, E. A., Watanabe, A., Watkins, W., Dranoff, J. A., & Mehal, W. Z. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00208.2006 · Cited by 78
“very large body of literature on the regulation by adenosine of adaptive responses to tissue injury in a number of organs, but very little is known about its role in liver injury and repair(8).”
Purinergic signalling in epithelial ion transport: regulation of secretion and absorption
Novak, I. (2010) · Acta Physiologica · doi:10.1111/j.1748-1716.2010.02225.x · Cited by 86
“It can bind to 502 2011 The Author Acta Physiologica 2011 Scandinavian Physiological Society, doi: 10.1111/j.1748-1716.2010.02225.x plasma membrane P1 receptors, better known as adenosine receptors (A1, A2A, A2B, A3; Fredholm et al. 2001, Jacobson & Gao 2006).”
BackgroundInfluentialHyperkalemic cardioplegia for adult and pediatric surgery: end of an era?
Dobson, G. P., Faggian, G. G., Onorati, F., & Vinten‐Johansen, J. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00228 · Cited by 98
“…Hove et al., 2007; Wang et al., 2007), anti-arrhythmic (Camm and Garratt, 1991; Alexander et al., 1999; Kucera et al., 2002; Wyman et al., 2004; Jacobson and Gao, 2006) and anti-inflammatory properties (Goldstein et al., 1977; McGregor et al., 1980; Tomoda et al., 1990; Sasagawa, 1991;…”
Molecular Evidence of Adenosine Deaminase Linking Adenosine A2A Receptor and CD26 Proteins
Moreno, E., Canet, J., Gracia, E., Lluís, C., Mallol, J., Canela, E. I., Cortés, A., & Casadó, V. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00106 · Cited by 89
“The activation of A2AR can also activate protein kinase C (PKC), through cyclic AMP-dependent and -independent mechanisms (Jacobson and Gao, 2006; Sheth et al., 2014; Cortés et al., 2015; Leiva et al., 2017).”
BackgroundAdenosine A2b receptor promotes progression of human oral cancer
Kasama, H., Sakamoto, Y., Kasamatsu, A., Okamoto, A., Koyama, T., Minakawa, Y., Ogawara, K., Yokoe, H., Shiiba, M., Tanzawa, H., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1577-2 · Cited by 88
“Growing evidence indicates that the adenosine-receptor pathway also may be a promising therapeutic target in a wide range of conditions, including cerebral and cardiac ischemic diseases, sleep disorders, immune and inflammatory disorders, and cancer [9].”
BackgroundMoonlighting Adenosine Deaminase: A Target Protein for Drug Development
Cortés, A., Gracia, E., Moreno, E., Mallol, J., Lluís, C., Canela, E. I., & Casadó, V. (2014) · Medicinal Research Reviews · doi:10.1002/med.21324 · Cited by 77
Metadata
- Authors
- Jacobson, K. A., & Gao, Z.-G.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Jacobson, Kenneth A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 247-264
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3463109
- OpenAlex
- W1985598247
- Cited by
- 1,431
- References
- 215
- Citations by year
- 2026: 34 · 2025: 50 · 2024: 52 · 2023: 55 · 2022: 80 · 2021: 58 · 2020: 65 · 2019: 79 · 2018: 66 · 2017: 59 · 2016: 65 · 2015: 64 · 2014: 80 · 2013: 80 · 2012: 83
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (Z01DK031117)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- adenosine receptors, adenosine receptor agonists, adenosine receptor antagonists, selective ligands, caffeine, cardiovascular disease, ischemic diseases, sleep disorders, inflammatory diseases, cancer, neurological disorders, drug development
- MeSH terms
- Animals, Disease, Drug Therapy, Humans, Ligands, Structure-Activity Relationship, Molecular Structure, Signal Transduction, Receptors, Purinergic P1, Purinergic P1 Receptor Agonists, Purinergic P1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.